Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + relatlimab fixed-dose combination with chemotherapy versus pembrolizumab with chemotherapy in first-line PD-L1-positive non-squamous advanced NSCLC
NL-OMON60654Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of nivolumab, relatlimab and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall survival. Started Aug 2025; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60654.